trending Market Intelligence /marketintelligence/en/news-insights/trending/0kbe3nht2wibpf6lazppew2 content esgSubNav
In This List

Pfizer injects $600M in venture investment arm

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Pfizer injects $600M in venture investment arm

Pfizer Inc. is investing $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the U.S. drug giant's venture investment vehicle.

Pfizer Ventures will seek to invest about 25% of its available capital, equivalent to about $150 million, in early stage neuroscience companies — or those focused on the study of the nervous system.

The vehicle will continue to invest in other fields such as oncology, inflammation and immunology, rare disease, internal medicine and vaccines.

Pfizer Ventures actively manages an existing investment portfolio of more than 40 companies. Combined with about $500 million invested to date, the additional funding brings Pfizer Ventures' total assets under management to more than $1 billion.